Exosomal NAMPT from Engineered Mesenchymal Stem Cells Mitigates Aortic Stenosis via Metabolic and Anti-Inflammatory Pathways
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms27010256 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Dipan Kumar Kundu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Northeast Ohio Medical University, Rootstown, OH 44272, USA. Hauptthemen laut MEDLINE: Aortic Valve Stenosis, Mesenchymal Stem Cells, Nicotinamide Phosphoribosyltransferase, Exosomes. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NEOMED internal funding.
Abstract (Originalsprache)
The aim of this study was to determine whether exosomes from Nicotinamide phosphoribosyltransferase (NAMPT)-overexpressing mesenchymal stem cells (MSC NAMPT-Exo) can attenuate aortic stenosis (AS) and explored the underlying mechanism. NAMPT expression was examined in EC CXCR4 KO (AS) mouse hearts. Six-week-old AS mice received weekly injections of NAMPT-Exo, MSC-Exo, or PBS for three weeks, followed by echocardiography and histological examination of the valves (H&E, Alizarin Red, immunofluorescence). Cardiac ECs from control, AS, and NAMPT-Exo-treated mice were analyzed for miRNA expression (miR-146a-3p/5p, miR-125b-5p, miR-142a-5p). NAMPT expression was decreased in AS hearts. Treatment with NAMPT-Exo reduced aortic valve peak velocity, valvular thickening, and microcalcifications, while improving ejection fraction, fractional shortening, and ventricular dimensions. AS endothelial cells showed elevated levels of miR-146a-3p, miR-146a-5p, and miR-142a-5p, NAMPT-Exo specifically normalized miR-146a-3p. Histology revealed EndMT in AS valves, which was diminished by NAMPT-Exo. In vitro, inhibiting miR-146a-3p suppressed TGF-β-induced EndMT. Our results demonstrate that NAMPT-enriched MSC-derived exosomes effectively slow the progression of AS. Additionally, our findings highlight miR-146a-3p as a key regulator of EndMT, suggesting it as a potential molecular target for future therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Sciences, Northeast Ohio Medical University, Rootstown, OH 44272, USA.
- Department of Biomedical Sciences, Kent State University, Kent, OH 44240, USA.
- Advanced Materials and Liquid Crystal Institute, Kent State University, Kent, OH 44240, USA.
- College of Medicine, University of Arizona, Tucson, AZ 85721, USA.
ORCID-Profile: Dipan Kumar Kundu, Min Gao, Liya Yin, Vahagn Ohanyan, William M Chilian, Feng Dong
Förderung
- NEOMED internal funding
Zitieren
APA
Kundu, D. K., Kiedrowski, M., Gadd, J., Gao, M., Evan, M., Wang, Y., Yin, L., Ohanyan, V., Chilian, W. M., & Dong, F. (2025). Exosomal NAMPT from Engineered Mesenchymal Stem Cells Mitigates Aortic Stenosis via Metabolic and Anti-Inflammatory Pathways. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27010256
Vancouver
Kundu DK, Kiedrowski M, Gadd J, Gao M, Evan M, Wang Y, et al. Exosomal NAMPT from Engineered Mesenchymal Stem Cells Mitigates Aortic Stenosis via Metabolic and Anti-Inflammatory Pathways. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms27010256
BibTeX
@article{Kundu2025,
author = {Kundu, Dipan Kumar and Kiedrowski, Matthew and Gadd, James and Gao, Min and Evan, Madeline and Wang, Yang and Yin, Liya and Ohanyan, Vahagn and Chilian, William M and Dong, Feng},
title = {Exosomal NAMPT from Engineered Mesenchymal Stem Cells Mitigates Aortic Stenosis via Metabolic and Anti-Inflammatory Pathways},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms27010256}
}
EUVIMED